*Note: All information and materials provided has expired for CME credit possibilities and is solely to be used for informational purposes only.
The incretin hormone GLP-1 acts as a satiety hormone, making it a potentially attractive target for the treatment of obesity. This lecture will discuss mechanisms by which GLP-1 affects satiety, review the efficacy of GLP-1-based therapies as weight loss agents in patients with type 2 diabetes, and include preliminary clinical trial data in patients without diabetes mellitus. The safety and current concerns surrounding this type of therapy will also be reviewed.
Disclosures (at time of recording): Speaker:
Barbara McGowan, MD, FRCP, PhD: Novo Nordisk: Principal Investigator – SCALE Study and Administrative Board Member
William McCarthy, MD, FOMA: Ridgetop Research: Offered Expert Opinion on Qsymia
Cookies are small pieces of information that are stored by your browser on your computer’s hard drive.
You can delete or block cookies within your browser settings.
Should you opt to do this, some parts of our site may not work.
For more information, including instructions on how to remove the cookies that have been placed,